Rifaximin, a minimally absorbed antibiotic, has become a cornerstone therapy for several gastrointestinal disorders, including irritable bowel syndrome with diarrhea (IBS-D) and hepatic encephalopathy. Despite its established use, access to rifaximin varies significantly across global markets, with cost barriers posing challenges in some regions. In contrast, in many Asian countries, the same medication is available
Why does rifaximin cost 95 percent more in the U.S. than in Asia? originally appeared in KevinMD.com.
